Skip to main content

Table 3 Aspirin use after diagnosis (time-varying) and risk of breast cancer-specific death within clinical subgroups

From: No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study

  1. CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio
  2. aAdjusted for age, stage, education, comorbidity (including inflammatory diseases, heart disease, cerebrovascular disease, atherosclerotic disease, thromboembolic venous disease, hyperlipidemia, hypertension, peptic ulcer, liver disease, asthma), year of diagnosis, region and aspirin use before diagnosis
  3. Bold data represent significant values